John Johnson

John Johnson has an estimated net worth of $5.8 Million. This is based on reported shares across multiple companies, which include Sucampo Pharmaceuticals, Inc., LILLY ELI & CO, SAVIENT PHARMACEUTICALS INC, MELINTA THERAPEUTICS, INC. /NEW/, HISTOGENICS CORP, Verastem, Inc., AVEO PHARMACEUTICALS INC, Xeris Biopharma Holdings, Inc., Axogen, Inc., Strongbridge Biopharma plc, DENDREON CORP, PORTOLA PHARMACEUTICALS INC, TRANZYME INC, IMCLONE SYSTEMS INC, and Applied Therapeutics, Inc..

2021 was John Johnson's most active year for acquiring shares with 18 total transactions. John Johnson's most active month to acquire stocks was the month of May. 2025 was John Johnson's most active year for disposing of shares, totalling 9 transactions. John Johnson's most active month to dispose stocks was the month of November. 2012 saw John Johnson paying a total of $18,960,030.16 for 2,113,207 shares, this is the most they've acquired in one year. In 2011 John Johnson cashed out on 500,000 shares for a total of $4,615,000.00, their largest year based on trade value.